The Experts below are selected from a list of 36 Experts worldwide ranked by ideXlab platform
Zehua Wang - One of the best experts on this subject based on the ideXlab platform.
-
Tumor-associated Lymphatic endothelial cell promotes invasion of cervical cancer cells
APMIS : acta pathologica microbiologica et immunologica Scandinavica, 2013Co-Authors: Liqiong Cai, Shouhua Yang, Hui Ding, Jing Cai, Zehua WangAbstract:The most common way for cervical cancer to spread is through the Lymphatic System. Tumor-associated Lymphatic endothelial cell (TLEC) has been considered to play a crucial role in metastasis of certain cancers. The aim of this study was to isolate TLEC from human cervical cancers and explore its involvement in metastasis-associated behaviors in vitro. Lymphatic vessels in 62 cervix tissue specimens ranging from cervical intraepithelial neoplasia (CIN) to advanced invasive cancer were detected using immunochemical staining with D2-40 antibody. Relation of Lymphatic vessel density (LVD) to clinicopathological characters was analyzed. Primary TLECs were isolated by LYVE-1 immuno-magnetic beads from cervical cancer tissues and verified through expression of LEC markers Prox-1 and D2-40, and then cultured in vitro. Invasiveness and viability of cells were assessed by transwell assay and typan blue exclusion, respectively. Our results showed that higher LVD was significantly associated with advanced FIGO stage, pelvic Lymphatic nodal metastasis (LNM), and poorer cell differentiation. TLECs were successfully primarily isolated and cultured in vitro. Supernatant of TLEC enhanced invasiveness of Hela cell, but did not significantly affect cell viability. In conclusion, TLECs might actively promote Lymphatic metastasis of cervical cancer. Further studies are needed to demonstrate the underlying mechanisms.
Michael Gnant - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer
Annals of surgery, 2004Co-Authors: Sebastian F. Schoppmann, Guenther Bayer, Klaus Aumayr, Susanne Taucher, Silvana Geleff, Margaretha Rudas, Ernst Kubista, Hubert Hausmaninger, Hellmut Samonigg, Michael GnantAbstract:The major cause of death from breast cancer is dissemination of the primary Tumor leading to formation of metastases. Spread to axillary lymph nodes is often the first step of generalization.1 Thus, the presence of lymph node metastasis represents a major criterion for evaluating the potential prognosis of breast cancer patients and predicts the choice of additional chemotherapy and/or radiation therapy after surgery of primary Tumor.2 Tumor-associated Lymphatic vessels are considered as the main rout of Tumor cells to axillary lymph nodes.3 Lymphovascular invasion (LVI) of Tumor cells is a prerequisite for the dissemination via the Lymphatic System. Tumor cells exposed to more microvessels are more likely to spread to distant sites and to lymph nodes.4,5 Therefore, antilymphangiogenic therapies have been suggested as novel therapeutic concepts, and first preliminary experimental studies show promising results.6 Studies of Lymphatic vessels and lymphogenic metastasis have been hampered by the lack of specific Lymphatic markers.7 Until recently, immunohistochemical identification of Lymphatic vessels was, somehow unreliably, achieved by comparing staining of pan-endothelial markers like PECAM-1/CD318,9 with markers of the basal lamina, eg, collagen type IV.10 Vessels that reacted with CD31 but lacked a basement membrane staining with red blood cells in their lumens were deemed Lymphatic.9 More recently, Lymphatic vessel identification has been made possible by the identification of the vascular endothelial growth factor receptor-3 (VEGFR-3), which is predominantly expressed on Lymphatic endothelium in normal adult tissue but is also up-regulated on blood vessel endothelium in Tumors limiting its use in visualizing Tumor-associated lymphangiogenesis.11,12 Until now, two studies about the clinical relevance of lymphangiogenesis in human breast cancer exist: Jacquemier et al using VEGFR-3 as Lymphatic marker saw no association between their microvessel count and the patient's lymph node status or overall survival.13 The second study by Nathanson et al applying an immunohistochemical staining combination with factor VIII, collagen 4, and VEGFR-3 to identify Lymphatic vessels, in contrast, described a significant correlation between high VEGFR-3-microvessel density and the patient's lymph node status.3 The predictive value of LVI, determined by the presence of neoplastic cell emboli within spaces showing a clear endothelial lining, is also being discussed controversially.14–16 The identification of podoplanin as a specific marker of the Lymphatic endothelium and the development of a polyclonal antibody have enabled us to selectively stain Lymphatic vessels.17 Therefore, to our knowledge, this study presents the first data correlating lymphangiogenesis and lymphovascular invasion on the prognosis in a representative cohort of breast cancer patients. Although respective, preliminary evidence does exist,3,13,15,18 the prognostic relevance of lymphangiogenesis and lymphovascular invasion in breast cancer has not yet been investigated in a large cohort using a specific Lymphatic marker. The aim of this study was the investigation of lymphangiogenesis and lymphovascular invasion, its predictive role of lymph node involvement, and its prognostic relevance in a large series of breast cancer with long-term follow-up.
Liqiong Cai - One of the best experts on this subject based on the ideXlab platform.
-
Tumor-associated Lymphatic endothelial cell promotes invasion of cervical cancer cells
APMIS : acta pathologica microbiologica et immunologica Scandinavica, 2013Co-Authors: Liqiong Cai, Shouhua Yang, Hui Ding, Jing Cai, Zehua WangAbstract:The most common way for cervical cancer to spread is through the Lymphatic System. Tumor-associated Lymphatic endothelial cell (TLEC) has been considered to play a crucial role in metastasis of certain cancers. The aim of this study was to isolate TLEC from human cervical cancers and explore its involvement in metastasis-associated behaviors in vitro. Lymphatic vessels in 62 cervix tissue specimens ranging from cervical intraepithelial neoplasia (CIN) to advanced invasive cancer were detected using immunochemical staining with D2-40 antibody. Relation of Lymphatic vessel density (LVD) to clinicopathological characters was analyzed. Primary TLECs were isolated by LYVE-1 immuno-magnetic beads from cervical cancer tissues and verified through expression of LEC markers Prox-1 and D2-40, and then cultured in vitro. Invasiveness and viability of cells were assessed by transwell assay and typan blue exclusion, respectively. Our results showed that higher LVD was significantly associated with advanced FIGO stage, pelvic Lymphatic nodal metastasis (LNM), and poorer cell differentiation. TLECs were successfully primarily isolated and cultured in vitro. Supernatant of TLEC enhanced invasiveness of Hela cell, but did not significantly affect cell viability. In conclusion, TLECs might actively promote Lymphatic metastasis of cervical cancer. Further studies are needed to demonstrate the underlying mechanisms.
Sebastian F. Schoppmann - One of the best experts on this subject based on the ideXlab platform.
-
Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer
Annals of surgery, 2004Co-Authors: Sebastian F. Schoppmann, Guenther Bayer, Klaus Aumayr, Susanne Taucher, Silvana Geleff, Margaretha Rudas, Ernst Kubista, Hubert Hausmaninger, Hellmut Samonigg, Michael GnantAbstract:The major cause of death from breast cancer is dissemination of the primary Tumor leading to formation of metastases. Spread to axillary lymph nodes is often the first step of generalization.1 Thus, the presence of lymph node metastasis represents a major criterion for evaluating the potential prognosis of breast cancer patients and predicts the choice of additional chemotherapy and/or radiation therapy after surgery of primary Tumor.2 Tumor-associated Lymphatic vessels are considered as the main rout of Tumor cells to axillary lymph nodes.3 Lymphovascular invasion (LVI) of Tumor cells is a prerequisite for the dissemination via the Lymphatic System. Tumor cells exposed to more microvessels are more likely to spread to distant sites and to lymph nodes.4,5 Therefore, antilymphangiogenic therapies have been suggested as novel therapeutic concepts, and first preliminary experimental studies show promising results.6 Studies of Lymphatic vessels and lymphogenic metastasis have been hampered by the lack of specific Lymphatic markers.7 Until recently, immunohistochemical identification of Lymphatic vessels was, somehow unreliably, achieved by comparing staining of pan-endothelial markers like PECAM-1/CD318,9 with markers of the basal lamina, eg, collagen type IV.10 Vessels that reacted with CD31 but lacked a basement membrane staining with red blood cells in their lumens were deemed Lymphatic.9 More recently, Lymphatic vessel identification has been made possible by the identification of the vascular endothelial growth factor receptor-3 (VEGFR-3), which is predominantly expressed on Lymphatic endothelium in normal adult tissue but is also up-regulated on blood vessel endothelium in Tumors limiting its use in visualizing Tumor-associated lymphangiogenesis.11,12 Until now, two studies about the clinical relevance of lymphangiogenesis in human breast cancer exist: Jacquemier et al using VEGFR-3 as Lymphatic marker saw no association between their microvessel count and the patient's lymph node status or overall survival.13 The second study by Nathanson et al applying an immunohistochemical staining combination with factor VIII, collagen 4, and VEGFR-3 to identify Lymphatic vessels, in contrast, described a significant correlation between high VEGFR-3-microvessel density and the patient's lymph node status.3 The predictive value of LVI, determined by the presence of neoplastic cell emboli within spaces showing a clear endothelial lining, is also being discussed controversially.14–16 The identification of podoplanin as a specific marker of the Lymphatic endothelium and the development of a polyclonal antibody have enabled us to selectively stain Lymphatic vessels.17 Therefore, to our knowledge, this study presents the first data correlating lymphangiogenesis and lymphovascular invasion on the prognosis in a representative cohort of breast cancer patients. Although respective, preliminary evidence does exist,3,13,15,18 the prognostic relevance of lymphangiogenesis and lymphovascular invasion in breast cancer has not yet been investigated in a large cohort using a specific Lymphatic marker. The aim of this study was the investigation of lymphangiogenesis and lymphovascular invasion, its predictive role of lymph node involvement, and its prognostic relevance in a large series of breast cancer with long-term follow-up.
Hong-wei Tian - One of the best experts on this subject based on the ideXlab platform.
-
Tumor Lymphangiogenesis and Lymphangiogenic Growth Factors
Archives of medical research, 2008Co-Authors: Hong-wei TianAbstract:Recent studies have revealed that malignant Tumors can actively induce the formation of new Lymphatic vessels and metastasize through the Lymphatic System. Tumor-induced lymphangiogenesis driven by Tumors expressed lymphangiogenic growth factors such as VEGF family, fibroblast growth factor 2 (FGF-2), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), and platelet-derived growth factors (PDGFs) is correlated with lymph node metastasis in experimental cancer models and in several types of human cancers. Tumor- induced lymphangiogenesis has now been firmly established as a novel mechanism for cancer progression and lymph node metastasis. Recent studies indicate that blockade of the lymphangiogenic growth factors pathway inhibits Tumor spread to lymph nodes and likely beyond. The potential effects of most of these newly identified Lymphatic growth factors on Tumor-induced lymphangiogenesis and lymph node metastasis remain to be further investigated. A number of questions remain to be answered concerning the potential efficacy of targeting at Tumor-induced lymphangiogenesis for inhibiting Tumor spread to lymph nodes.
